Table 3. Univariate and multivariate analysis of survival for 179 patients with an EGFR-activating mutation.

	N	Events	Univariate			Multivariate
			OS (month)	95% CI	p	p	HR (95% CI)
Age
≤65	140	101	17.5	14.978–20.022	0.927
>65	39	28	14.3	7.446–21.154
Gender
Male	78	60	16.1	12.891–19.309	0.059
Female	101	69	19.6	14.396–24.804
Smoking status
Non-smoking	125	90	17.5	14.222–20.778	0.502
Smoking	54	39	19.0	15.203–22.797
PS score
0–1	170	122	17.8	15.363–20–20.237	0.469
≥2	9	7	12.0	0.605–23.395
Histological type*
Adenocarcinoma	173	123	18.0	15.097–20.903	<0.001	<0.001	5.650 (2.223–14.362)
Squamous	5	5	7.3	6.497–9.503
Disease type
Recurrent disease	51	31	30.1	3.685–56.515	0.028	0.002	1.976 (1.291–3.025)
Local or metastatic disease	128	98	17.0	13.564–20.436
EGFR TKI therapy
Yes	117	77	24.3	18.076–30.524	<0.001	<0.001	2.525 (1.748–3.646)
No	62	52	10.8	8.397–13.203

P values were listed in the l table. *1 patient with large cell lung cancer was not enrolled.